Gehan E A, Nesbit M E, Burgert E O, Viettit J, Tefft M, Perez C A, Kissane J, Hempel C
Natl Cancer Inst Monogr. 1981 Apr(56):273-8.
Patient characteristics of 272 patients entered in a clinical trial conducted by the Pediatric Intergroup Ewing's Sarcoma Committee between June 1972 and November 1978 were examined for their relationship to prognosis. Prognosis was defined as disease-free survival time (time to local recurrence and/or metastatic disease) and overall survival time; all times were measured from the start of treatment. In a multivariate regression model, primary site of disease was the major variable that influenced prognosis, and patients with pelvic sites had the least favorable prognoses, followed by those with proximal and rib sites. The most favorable sites were distal and other. The median disease-free and survival times in weeks by primary site were, respectively: pelvis (69, 112), proximal (102, 141), rib (105, 109+), distal (226+, 240), and other (96+, 199+). Females had better prognoses than males; the median survival times were 197 and 147 weeks, respectively. An abnormal liver function as indicated by an abnormal serum glutamic-oxaloacetic transaminase value (greater than 45 IU) was a bad prognostic sign, although only 8 patients had this finding; their median survival time was 94 weeks. Patients who had resections had a slight advantage in survival compared with those having biopsies, though the difference favoring resection patients was not consistent for both sexes in any primary site. Individual characteristics of the patients that were of prognostic significance were: blood lymphocyte counts (high counts favorable), polymorphonuclear leukocyte counts (high counts unfavorable), and time from symptoms to diagnosis (times less than 1 mol favorable). Patients who received treatment 2 had significantly poorer prognoses than those given treatments 1 or 3. The median disease-free and survival times by treatment were (in wk): 1 (134, 198+), 2 (81, 120), and 3 (123, 182).
对1972年6月至1978年11月期间由小儿肉瘤协作组进行的一项临床试验中纳入的272例患者的特征进行了检查，以确定它们与预后的关系。预后定义为无病生存时间（至局部复发和/或转移性疾病的时间）和总生存时间；所有时间均从治疗开始时起测量。在多变量回归模型中，疾病的原发部位是影响预后的主要变量，骨盆部位的患者预后最差，其次是近端和肋骨部位的患者。最有利的部位是远端和其他部位。按原发部位划分，无病和生存时间的中位数（以周为单位）分别为：骨盆（69, 112）、近端（102, 141）、肋骨（105, 109+）、远端（226+, 240）和其他（96+, 199+）。女性的预后优于男性；中位生存时间分别为197周和147周。血清谷氨酸草酰乙酸转氨酶值异常（大于45 IU）表明肝功能异常是一个不良预后指标，尽管只有8例患者有此发现；他们的中位生存时间为94周。与接受活检的患者相比，接受手术切除的患者在生存方面略有优势，尽管在任何原发部位，有利于手术切除患者的差异在两性中并不一致。对预后有意义的患者个体特征包括：血淋巴细胞计数（计数高有利）、多形核白细胞计数（计数高不利）以及从症状出现到诊断的时间（时间少于1个月有利）。接受治疗2的患者预后明显比接受治疗1或3的患者差。按治疗划分，无病和生存时间的中位数（以周为单位）分别为：1（134, 198+）、2（81, 120）和3（123, 182）。
